Overview

Toclizumam Versus Dexamethasone in Severe Covid-19 Cases

Status:
Completed
Trial end date:
2020-08-05
Target enrollment:
0
Participant gender:
All
Summary
randomized controlled trial comparing survival benefit of Tocilizumab therapy with dexamethasone in patients with severe COVID 19
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
South Valley University
Treatments:
Dexamethasone
Criteria
Inclusion Criteria:

- respiratory rate > 30 cycle/minute, Bilateral CT infiltration > 30%, PaO2/FiO2 ratio
<150 or saturation <90 on >6L/min, Two positive laboratory tests of: (CRP>100 g/dL,
lymphocytes<600 /mm3, D dimer>L, Ferritin >500)

Exclusion Criteria:

- Pediatric patients < 18 years old, patients with active bacterial or fungal infection
and patients who were not requiring supplemental oxygen